GO:0008024 cyclin/CDK positive transcription elongation factor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008024 describes the cyclin/CDK positive transcription elongation factor complex, also known as P-TEFb, which phosphorylates the CTD of RNA polymerase II to enable productive elongation.
• P-TEFb is composed of a cyclin (CycT1 or CycT2) and a cyclin-dependent kinase (CDK9), and its activity is essential for the transition from abortive to productive transcription elongation.
• The complex is recruited to promoters by transcription factors such as Myc, which mediates the final step in transcriptional activation of target genes like the cad promoter.
• Dysregulation of P-TEFb is implicated in cancer, cardiac hypertrophy, and HIV latency, making it a target for therapeutic intervention.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the function of P-TEFb components in health and disease.
• Understanding GO:0008024 provides insights into gene regulation, and EDITGENE offers specialized services to create custom cell models for studying this complex.
Description
The cyclin/CDK positive transcription elongation factor complex, designated GO:0008024, is a cellular component that plays a pivotal role in the regulation of gene expression. This complex, often referred to as P-TEFb, facilitates the transition from abortive to productive elongation by phosphorylating the C-terminal domain (CTD) of the large subunit of DNA-directed RNA polymerase II holoenzyme. The importance of this complex is underscored by its involvement in diverse biological processes, including cell growth, differentiation, and development, as well as its implication in various human diseases such as cancer and HIV latency. Researchers studying transcriptional regulation and disease mechanisms require a detailed understanding of the components, assembly, and regulation of this complex. This article provides a comprehensive overview of GO:0008024, integrating authoritative QuickGO data and verified PubMed literature to support research-grade insights. By exploring its structure, function, and experimental models, we aim to equip scientists with the knowledge to investigate this complex using advanced CRISPR-based approaches.
cyclin/CDK positive transcription elongation factor complex At A Glance
| GO ID | GO:0008024 |
|---|---|
| GO term | cyclin/CDK positive transcription elongation factor complex |
| Ontology | cellular_component |
| Synonym | positive transcription elongation factor complex b |
| Major function | Phosphorylates CTD of RNA polymerase II to promote productive elongation |
| Complex components | Cyclin (e.g., CCNT1) and cyclin-dependent kinase (e.g., CDK9) |
| Subcellular location | Nucleus |
| Associated processes | Transcription elongation, gene expression regulation |
| Disease relevance | Cancer, HIV latency, cardiac hypertrophy |
What Is GO:0008024?
GO:0008024, the cyclin/CDK positive transcription elongation factor complex, is a transcription elongation factor complex that facilitates the transition from abortive to productive elongation by phosphorylating the CTD domain of the large subunit of DNA-directed RNA polymerase II holoenzyme. It contains a cyclin and a cyclin-dependent protein kinase catalytic subunit. This definition captures the essential biochemical function and composition of the complex, highlighting its role in transcriptional control.
Why Is cyclin/CDK positive transcription elongation factor complex Important in Cell Biology?
The cyclin/CDK positive transcription elongation factor complex is crucial for the regulation of gene expression at the level of transcription elongation. By phosphorylating the CTD of RNA polymerase II, it enables the polymerase to overcome promoter-proximal pausing and enter productive elongation, a key checkpoint in gene regulation. This complex is targeted by various transcription factors, such as Myc, to activate specific gene programs. Dysregulation of P-TEFb activity is associated with a range of pathological conditions, including cancer, where it can drive oncogenic transcription, and HIV, where it controls viral latency. Therefore, understanding the function and regulation of GO:0008024 is essential for both basic research and therapeutic development.
• Regulates transcription elongation of diverse genes, including those involved in cell cycle and apoptosis.
• Recruited by transcription factors like Myc to mediate final steps in transcriptional activation.
• Implicated in cancer pathogenesis through aberrant activation of oncogenes.
• Plays a role in HIV latency and reactivation, making it a target for latency-reversing agents.
• Involved in cardiac hypertrophy and heart failure via regulation of cardiac gene expression.
• Essential for embryonic development and stem cell maintenance.
• Target for small molecule inhibitors (e.g., CDK9 inhibitors) in clinical trials for cancer.
• Key component of the super elongation complex (SEC) and other regulatory machineries.
• Subject to regulation by cellular signaling pathways and non-coding RNAs.
• Provides a model for studying the interplay between transcription and RNA processing.
What Happens During cyclin/CDK positive transcription elongation factor complex?
Recruitment to Target Genes
In simple terms: The complex is brought to specific genes by transcription factors.
The cyclin/CDK positive transcription elongation factor complex is recruited to target gene promoters by sequence-specific transcription factors. For example, the transcription factor Myc interacts with P-TEFb and recruits it to the cad promoter, mediating the final step in transcriptional activation. This recruitment is a critical step in transitioning RNA polymerase II from a paused state to productive elongation.
Phosphorylation of RNA Polymerase II CTD
In simple terms: The complex adds phosphate groups to RNA polymerase II, activating it.
Once recruited, the CDK9 subunit of P-TEFb phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II. This phosphorylation event, particularly at serine 2 of the CTD heptad repeats, is essential for the transition from abortive to productive elongation. It also facilitates the recruitment of factors involved in RNA processing and chromatin modification.
Transition to Productive Elongation
In simple terms: Phosphorylation allows RNA polymerase II to efficiently synthesize full-length RNA.
The phosphorylation of RNA polymerase II CTD by P-TEFb triggers the release of paused polymerase and promotes processive elongation. This transition is a key regulatory checkpoint, and its dysregulation can lead to aberrant gene expression. The complex thus plays a central role in controlling the output of gene expression programs.
Coupling with RNA Processing
In simple terms: The complex also helps coordinate RNA synthesis with RNA processing.
Phosphorylation of the CTD by P-TEFb creates a platform for the recruitment of RNA processing factors, including those involved in capping, splicing, and polyadenylation. This coupling ensures that nascent RNA transcripts are properly processed as they are synthesized, contributing to the fidelity of gene expression.
Key Genes Involved in GO:0008024 cyclin/CDK positive transcription elongation factor complex
The following genes encode components and regulators of the cyclin/CDK positive transcription elongation factor complex, with their roles and research relevance summarized.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDK9 | Catalytic subunit; phosphorylates RNA Pol II CTD | Target for cancer therapy; knockout studies show essential role in transcription |
| CCNT1 | Regulatory cyclin subunit; activates CDK9 | Knockout leads to loss of P-TEFb activity; implicated in HIV latency |
| CCNT2 | Alternative cyclin subunit; forms P-TEFb in specific contexts | Tissue-specific functions; potential redundancy with CCNT1 |
| MYC | Transcription factor; recruits P-TEFb to target genes | Oncogene; point mutations used to study recruitment mechanisms |
| BRD4 | Chromatin reader; recruits P-TEFb to acetylated chromatin | Target for BET inhibitors; knock-in of tagged BRD4 for imaging |
| AFF4 | Component of super elongation complex; interacts with P-TEFb | Knockout affects SEC assembly and transcription |
| ELL2 | Elongation factor; part of SEC | Overexpression enhances elongation; relevant in cancer |
| MLLT3 | Fusion partner in leukemia; interacts with P-TEFb | Knock-in models for leukemia research |
| HEXIM1 | Inhibitor of P-TEFb; binds to 7SK snRNA | Knockout releases P-TEFb; studies on HIV latency |
| 7SK snRNA | Non-coding RNA; sequesters P-TEFb in inactive complex | Knockdown alters P-TEFb availability; models for RNA-based regulation |
| LARP7 | Binds 7SK snRNA; stabilizes inactive P-TEFb complex | Knockout disrupts 7SK complex; studies on transcription regulation |
| MEPCE | Methylates 7SK snRNA; regulates P-TEFb complex | Knockout affects 7SK stability; potential role in development |
| CDK9 (isoform 2) | Alternative isoform; may have distinct functions | Isoform-specific knockout to study differential roles |
| CCNT1 (mutant) | Phosphorylation-deficient mutant; used to study CTD phosphorylation | Point mutation knock-in to dissect signaling |
| CDK9 (D167N) | Kinase-dead mutant; dominant-negative | Overexpression to inhibit P-TEFb activity |
| BRD4 (BD1 mutant) | Acetyl-lysine binding mutant; fails to recruit P-TEFb | Point mutation knock-in to study chromatin recruitment |
| MYC (T58A) | Stabilized mutant; enhances P-TEFb recruitment | Knock-in for cancer modeling |
| AFF4 (tagged) | Epitope-tagged for purification | Knock-in for proteomics and imaging |
How Is cyclin/CDK positive transcription elongation factor complex Regulated?
The activity of the cyclin/CDK positive transcription elongation factor complex is tightly regulated at multiple levels. The complex is sequestered in an inactive state by the 7SK small nuclear ribonucleoprotein (snRNP) complex, which includes HEXIM1, LARP7, and MEPCE. Release from this inhibitory complex is triggered by various cellular signals, including stress and transcriptional activation, allowing P-TEFb to phosphorylate RNA polymerase II. Additionally, the kinase activity of CDK9 is regulated by phosphorylation and dephosphorylation events, and its stability is controlled by ubiquitin-proteasome pathways. Transcription factors such as Myc can directly recruit P-TEFb to specific promoters, providing gene-specific regulation. Furthermore, the complex is a target of post-translational modifications, including acetylation and methylation, which modulate its interactions and activity. Understanding these regulatory mechanisms is essential for comprehending how P-TEFb coordinates gene expression in response to cellular cues.
cyclin/CDK positive transcription elongation factor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDK9 | Cancer, cardiac hypertrophy | Knockout in cancer cell lines; overexpression in cardiomyocytes |
| CCNT1 | HIV latency, cancer | Knockout in T cells; knock-in of tagged CCNT1 for imaging |
| MYC | Burkitt lymphoma, other cancers | Point mutation knock-in (T58A) in cancer models |
| HEXIM1 | HIV latency, cancer | Knockout to release P-TEFb; overexpression to induce latency |
| BRD4 | Cancer, HIV latency | Knock-in of BD1 mutant; knockout to study recruitment |
Cancer
Dysregulation of the cyclin/CDK positive transcription elongation factor complex is frequently observed in cancer. Overexpression or hyperactivation of CDK9 and its cyclin partners leads to enhanced transcription of oncogenes and anti-apoptotic genes, promoting tumor growth and survival. For instance, Myc, a well-known oncogene, recruits P-TEFb to activate target genes involved in cell proliferation, and its deregulation contributes to many cancers. Consequently, CDK9 inhibitors are being developed as anticancer therapeutics, and CRISPR-based models are invaluable for validating these targets.
HIV Latency
P-TEFb plays a dual role in HIV-1 replication. It is required for Tat-mediated transactivation of the viral long terminal repeat (LTR) and for productive elongation of viral transcripts. However, in latently infected cells, P-TEFb is sequestered in an inactive complex, contributing to viral latency. Strategies to release P-TEFb from the 7SK snRNP, such as using BET inhibitors or PKC agonists, are being explored as latency-reversing agents. CRISPR knockout of HEXIM1 or other components can mimic this activation and provide insights into latency mechanisms.
Cardiac Hypertrophy
The cyclin/CDK positive transcription elongation factor complex is involved in the regulation of cardiac gene expression. Increased P-TEFb activity has been linked to pathological cardiac hypertrophy, where it drives the expression of fetal genes and promotes cardiomyocyte growth. Inhibition of CDK9 has been shown to attenuate hypertrophy in preclinical models. CRISPR-mediated knockout of CDK9 or its cyclin partners in cardiomyocytes can help elucidate the molecular mechanisms underlying this process.
From cyclin/CDK positive transcription elongation factor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of CDK9 loss on transcription? | CDK9 knockout cell line (e.g., HEK293T) followed by RNA-seq |
| How does CCNT1 phosphorylation regulate P-TEFb activity? | Point mutation knock-in of CCNT1 at phosphorylation sites |
| Where is P-TEFb localized in live cells? | Knock-in of fluorescent protein tag (e.g., GFP) at CDK9 locus |
| Does overexpression of MYC enhance P-TEFb recruitment? | Overexpression of MYC in cancer cell lines; ChIP-seq for P-TEFb |
| What is the role of HEXIM1 in HIV latency? | HEXIM1 knockout in latently infected T cells; reactivation assays |
| Can BRD4 mutations disrupt P-TEFb recruitment? | Knock-in of BRD4 BD1 mutant; co-immunoprecipitation |
How to Study the cyclin/CDK positive transcription elongation factor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Assessing transcriptional impact of P-TEFb knockout |
| ChIP-seq | Genome-wide binding of P-TEFb and RNA Pol II | Mapping recruitment sites and elongation marks |
| AP-MS | Protein-protein interactions | Identifying novel P-TEFb complex components |
| Live-cell imaging | Subcellular localization and dynamics | Tracking P-TEFb recruitment to transcription sites |
| CRISPR screen | Genes affecting cell fitness or drug response | Identifying synthetic lethal partners with CDK9 inhibition |
| Ribo-seq | Translation efficiency | Linking P-TEFb activity to protein synthesis |
| Proteomics | Protein abundance and modifications | Quantifying changes in P-TEFb subunits upon perturbation |
Transcriptomics (RNA-seq)
RNA sequencing (RNA-seq) is a powerful method to assess the global impact of P-TEFb on gene expression. By comparing wild-type and knockout cells, researchers can identify genes whose expression depends on the complex. For example, knockout of CDK9 leads to widespread changes in transcription, including reduced expression of genes involved in cell cycle and survival. RNA-seq can also reveal changes in alternative splicing and polyadenylation, as P-TEFb couples transcription with RNA processing.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry (AP-MS) can identify proteins that interact with P-TEFb components. Knock-in of epitope tags (e.g., FLAG, HA) at endogenous loci allows for purification of the complex under near-physiological conditions. This approach has been used to identify components of the super elongation complex (SEC) and other regulatory partners. Quantitative proteomics can also measure changes in protein abundance and post-translational modifications upon P-TEFb perturbation.
Imaging and Live-Cell Dynamics
Fluorescence microscopy, including live-cell imaging, can visualize the localization and dynamics of P-TEFb. Knock-in of fluorescent proteins (e.g., GFP) at the CDK9 or CCNT1 locus enables real-time tracking of the complex. For instance, FRAP (fluorescence recovery after photobleaching) can measure the mobility of P-TEFb at transcription sites. These methods provide spatiotemporal insights into how P-TEFb is recruited to genes and released from inhibitory complexes.
Genome Editing and Functional Genomics
CRISPR-Cas9 genome editing is instrumental for creating knockout, knock-in, and point mutation models to study P-TEFb. Large-scale CRISPR screens can identify genes that modulate P-TEFb activity or that are synthetically lethal with CDK9 inhibition. For example, a genome-wide knockout screen in cancer cells treated with CDK9 inhibitors can reveal resistance mechanisms. These functional genomics approaches accelerate target discovery and drug development.
How CRISPR Can Be Used to Study GO:0008024 cyclin/CDK positive transcription elongation factor complex
Knockout
CRISPR knockout of genes encoding P-TEFb components (e.g., CDK9, CCNT1) is used to study their essential roles in transcription and cell viability. For example, CDK9 knockout in cancer cell lines leads to rapid loss of RNA Pol II CTD phosphorylation and inhibition of global transcription, often resulting in cell death. Knockout models are also valuable for validating drug targets and understanding resistance mechanisms.
Point Mutation
Point mutations can be introduced to dissect specific functions of P-TEFb subunits. For instance, mutating the catalytic aspartate of CDK9 (D167N) creates a kinase-dead mutant that acts as a dominant-negative, allowing researchers to separate kinase-dependent and independent functions. Similarly, point mutations in the CTD of RNA Pol II can reveal the importance of specific phosphorylation sites for elongation.
Knock-in
Knock-in of tags (e.g., GFP, FLAG) or disease-associated mutations allows for precise tracking and functional analysis of P-TEFb. Tagged knock-in models enable live-cell imaging and proteomic studies without overexpression artifacts. For example, knocking in a fluorescent tag at the CDK9 locus allows visualization of the complex in real time. Disease-relevant mutations, such as those found in cancer, can be knocked in to study their effects on P-TEFb activity.
Overexpression
Overexpression of P-TEFb components or interacting factors (e.g., MYC, BRD4) is used to model oncogenic activation and to study the consequences of enhanced transcription elongation. For example, overexpression of MYC in cancer cells increases P-TEFb recruitment to target genes and promotes proliferation. Overexpression models are also useful for biochemical purification of the complex and for testing inhibitors.
How EDITGENE Supports cyclin/CDK positive transcription elongation factor complex Research
Researchers studying cyclin/CDK positive transcription elongation factor complex-related genes often need to determine whether a candidate gene is causally involved in transcriptional regulation, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to create custom cell models, enabling precise functional interrogation of GO:0008024 components and their regulators.
Contact EDITGENE today to design your custom CRISPR model for cyclin/CDK positive transcription elongation factor complex research.
Frequently Asked Questions About cyclin/CDK positive transcription elongation factor complex
What is GO:0008024?
GO:0008024 is the Gene Ontology term for the cyclin/CDK positive transcription elongation factor complex, also known as P-TEFb. It is a cellular component that phosphorylates the CTD of RNA polymerase II to promote productive transcription elongation.
What genes are involved in cyclin/CDK positive transcription elongation factor complex?
Key genes include CDK9 (catalytic subunit), CCNT1 and CCNT2 (cyclin subunits), and regulators such as HEXIM1, LARP7, MEPCE, and BRD4.
What is the function of P-TEFb?
P-TEFb phosphorylates the C-terminal domain of RNA polymerase II, enabling the transition from abortive to productive elongation and coupling transcription with RNA processing.
How is P-TEFb regulated?
P-TEFb is regulated by sequestration in the 7SK snRNP complex, by phosphorylation, and by recruitment to specific genes by transcription factors like Myc.
What diseases are associated with P-TEFb?
P-TEFb is implicated in cancer, HIV latency, and cardiac hypertrophy, among other conditions.
How can CRISPR be used to study P-TEFb?
CRISPR can create knockout, point mutation, knock-in, and overexpression models to dissect the roles of P-TEFb components in transcription and disease.
What is the difference between P-TEFb and TFIIH?
P-TEFb primarily phosphorylates serine 2 of the RNA Pol II CTD to promote elongation, while TFIIH phosphorylates serine 5 to initiate transcription. They act at different stages.
Can P-TEFb be targeted for cancer therapy?
Yes, CDK9 inhibitors are in clinical trials for cancer, and P-TEFb is considered a promising therapeutic target.
What is the role of CDK9 in transcription?
CDK9 is the kinase subunit of P-TEFb that phosphorylates RNA Pol II CTD and other substrates to stimulate elongation.
How does EDITGENE support P-TEFb research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, and library screening services to study P-TEFb and its regulators.
Conclusion
The cyclin/CDK positive transcription elongation factor complex (GO:0008024) is a master regulator of transcription elongation, essential for gene expression and implicated in numerous diseases. Understanding its components, assembly, and regulation provides critical insights into basic biology and disease mechanisms. Advanced CRISPR technologies, such as those offered by EDITGENE, empower researchers to create precise cell models to dissect P-TEFb function and identify new therapeutic targets. As research progresses, targeting this complex holds promise for treating cancer, HIV, and other disorders.
References
- 1. Eberhardy SR et al.. 2002. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter.. J Biol Chem 277(42):40156-62 PMID: 12177005
